NAMES AND DATABASE IDS
NAMES AND DATABASE IDS
Names Database IDs
|
IUPAC name
|
|
2-(5-benzoylthiophen-2-yl)propanoic acid
|
|
|
|
|
IUPAC Traditional name
|
|
|
Brand Name
|
|
Apo-Tiaprofenic Tablets
|
|
Dom-tiaprofenic
|
|
Novo-Tiaprofenic
|
|
Nu-Tiaprofenic
|
|
PMS-tiaprofenic
|
|
Surgam
|
|
Surgam SR
|
|
Tiaprofenic-200 - Tab
|
|
Tiaprofenic-300 - Tab
|
|
|
|
|
Synonyms
|
|
Surgam
|
|
Tiaprofen
|
|
α-(5-Benzoyl-2-thienyl)propionic Acid
|
|
5-Benzoyl-α-methyl-2-thiopheneacetic Acid
|
|
(RS)-Tiaprofenic Acid
|
|
(±)-Tiaprofenic Acid
|
|
FC 3001
|
|
RU 15060
|
|
Suralgan
|
|
2-(5-Benzyl-2-thienyl)propionsaeure
|
|
5-Benzoyl-alpha-methyl-2-thiopheneacetic acid
|
|
Acide tiaprofenique [inn-french]
|
|
Acido tiaprofenico [inn-spanish]
|
|
Acidum tiaprofenicum [inn-latin]
|
|
Tiaprofensaeure
|
|
Tiaprofenic acid
|
|
|
|
|
CAS Number
|
|
|
PubChem SID
|
|
|
PubChem CID
|
|
DATA SOURCES
DATA SOURCES
All Sources Commercial Sources Non-commercial Sources
|
Data Source
|
Data ID
|
Price
|
|
TRC
|
|
CALCULATED PROPERTIES
CALCULATED PROPERTIES
JChem
ALOGPS 2.1
|
Acid pKa
|
4.0343056
|
H Acceptors
|
3
|
H Donor
|
1
|
LogD (pH = 5.5)
|
2.1820798
|
LogD (pH = 7.4)
|
0.51959074
|
Log P
|
3.6586542
|
Molar Refractivity
|
69.1896 cm3
|
Polarizability
|
26.692451 Å3
|
Polar Surface Area
|
54.37 Å2
|
Rotatable Bonds
|
4
|
Lipinski's Rule of Five
|
true
|
|
Log P
|
3.22
|
LOG S
|
-3.91
|
Solubility (Water)
|
3.24e-02 g/l
|
PROPERTIES
PROPERTIES
Safety Information
Product Information
Bioassay(PubChem)
DETAILS
DETAILS
DrugBank
TRC
DrugBank -
DB01600
|
| Item |
Information |
|
Drug Groups
|
approved |
|
Description
|
Tiaprofenic acid is a non-steroidal anti-inflammatory drug of the arylpropionic acid (profen) class, used to treat pain, especially arthritic pain. |
| Indication |
Tiaprofenic acid is used to treat pain, especially arthritic pain. |
| Pharmacology |
Tiaprofenic acid is a non-steroidal anti-inflammatory drug of the arylpropionic acid (profen) class, used to treat pain, especially arthritic pain. The typical adult dose is 300mg twice daily. It is not recommended in children. |
| Affected Organisms |
| • |
Humans and other mammals |
|
| Biotransformation |
Hepatic (10%). Sparingly metabolised in the liver to two inactive metabolites. |
| Absorption |
Bioavailability is 90% following oral administration. |
| Half Life |
1.5-2.5 hours |
| External Links |
|
|
REFERENCES
REFERENCES
From Suppliers
Google Scholar
PubMed
Google Books
- • Clemence, F., et al.: Eur. J. Med. Chem., 9, 390 (1974)
- • Sorkin, E.M., et al.: Drugs, 29, 208 (1974)
- • Arrell, D., et al.: Clin. Pharmacol. Ther., 88, 120 (1974)
- Searching...Please wait...
PATENTS
PATENTS
PubChem Patent
Google Patent